|
1 Ciaraldi TP, Aroda V, Mudaliar S, et al. Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance[J]. J Clin Endocrinol Metab, 2009, 94(1) : 157-163.
|
|
2 Pfeifer SM, Kives S. Polycystic ovary syndrome in the adolescent [J]. Obstet Gynecol Clin North Am, 2009, 36(1) : 129-152.
|
|
3 Padmanabhan V. Polycystic ovary syndrome——"A riddle wrapped in a mystery inside an enigma" [J]. J Clin Endocrinol Metab,2009,94(6) :1883-1885.
|
|
4 Azziz R, Marin C, Hoq L, et al. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span[J]. J Clin Endocrinol Metab,2005,90(8):4650-4658.
|
|
5 Hardiman P, Antimo W. Polycystic ovary syndrome and endometrial carcinoma[J]. Lancet, 2003, 361: 1810-1812.
|
|
6 Kim JY, Song H, Kim H, et al. Transcriptional profiling with a pathway-oriented analysis identifies dysregulated molecular phenotypes in the endometrium of patients with polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2009, 94(4) : 1416-1426.
|
|
7 Stein IF, Leventhal M. Amenorrhea associated with bilateral polycystic ovaries[J]. Am J Obstet Gynecol, 1935 :181-191.
|
|
8 Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease[J]. J Clin Endocrinol Metab, 1980, 50(1) : 113-116.
|
|
9 Barba M, Schunemann HJ, Sperati F, et al. The effects of metformin on endogenous androgens and SHBG in women: A systematic review and meta-analysis[J]. Clin Endocrinol, 2009, 70 (5):661-670.
|
|
10 Motta AB. Mechanisms involved in metformin action in the treatment of polycystic ovary syndrome [J]. Curr Pharm Design, 2009,15(26):3074-3077.
|
|
11 Fruzzetti F, Perini D, Lazzarini V, et al. Hyperandrogenemia influences the prevalence of the metabolic syndrome abnormalities in adolescents with the polycystic ovary syndrome[J]. Gynecolog Endocrinol, 2009,25(5): 335-343.
|
|
12 Dunaif A, Graf M, Mandeli J, et al. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia[J]. J Clin Endocrinol Metab,1987,65(3) :499-507.
|
|
13 Asagami T, Holmes TH, Reaven G. Differential effects of insulin sensitivity on androgens in obese women with polycystic ovary syndrome or normal ovulation [ J]. Metabolism, 2008, 57(10):1355-1360.
|
|
14 Ben-Shlomo I, Homburg R, Shalev E. Hyperandrogenic anovulation (the polycystic ovary syndrome) —back to the ovary [J]? Hum Reprod Update, 1998, 4(3):296-300.
|
|
15 Hendriks ML, Ket JCF, Hompes PGA, et al. Why does ovarian surgery in PCOS help? Insight into the endocrine implications of ovarian surgery for ovulation induction in polycystic ovary syndrome[J]. Hum Reprod Update, 2007, 13(3):249-264.
|
|
16 Rosenfield RL, Bordini B. Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity [J]. Brain Res, 2010, 1364:186-197.
|
|
17 Teede H, Deeks A, Moran L. Polycystic ovary syndrome: A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan[J]. BMC Med,2010,8:41.
|
|
18 Legro RS. A 27-year-old woman with a diagnosis of polycystic ovary syndrome[J]. JAMA, 2007, 297(5) : 509-519.
|
|
19 Kaaja RJ, Poyhonen-Alho MK. Insulin resistance and sympathetic overactivity in women[J]. J Hypertens,2006,24(1) : 131-141.
|
|
20 Zborowski JV, Talbott EO, Cauley JA. Polycystic ovary syndrome, androgen excess, and the impact on bone[J]. Obstet Gynecol Clin North Am, 2001, 28(1) : 135-151.
|
|
21 Janssen OE, Mehlmauer N, Hahn S, et al. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome [J]. Eur J Endocrinol, 2004, 150(3) :363-369.
|
|
22 Apter D. Serum steroids and pituitary hormones in female puberty: A partly longitudinal study[J]. Clin Endocrinol (Oxf), 1980,12(2):107-120.
|
|
23 Hannon TS, Janosky J, Arslanian SA. Longitudinal study of physiologic insulin resistance and metabolic changes of puberty[J]. Pediatr Res, 2006, 60(6) : 759-763.
|
|
24 Shayya R, Chang RJ. Reproductive endocrinology of adolescent polycystic ovary syndrome[J]. BJOG,2010,117(2): 150-155.
|
|
25 Olufadi R, Byrne CD. Clinical and laboratory diagnosis of the metabolic syndrome[J]. J Clin Pathol,2008,61 (6):697-706.
|
|
26 Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents [J]. Am J Obstet Gynecol, 2010, 203(3):201.
|
|
27 Legro RS. Detection of insulin resistance and its treatment in adolescents with polycystic ovary syndrome [J]. J Pediatr Endocrinol, 2002, 15(Suppl 5): 1367-1378.
|
|
28 Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 1998, 83 (8) : 2694-2698.
|
|
29 Sultan C, Paris F. Clinical expression of polycystic ovary syndrome in adolescent girls[J]. Fertil Steril, 2006, 86(Suppl 1) :S6.
|
|
30 Zhang J, Xu LZ. Diagnosis of polycystic ovary syndrome [J/CD]. Chin J Obstet Gynecol Pediatr (Electron Ed), 2006, 2 ( 5) : 296-298.[张静，许良智.多囊卵巢综合征的诊断[J/CD].中华妇幼临床医学杂志：电子版，2006，2(5):296-298.]
|
|
31 Ben-Shlomo I, Franks S, Adashi EY. The polycystic ovary syndrome: Nature or nurture[J]? Fertil Steril, 1995, 63 (5) : 953-954.
|
|
32 Franks S, Mccarthy MI, Hardy K. Development of polycystic ovary syndrome: Involvement of genetic and environmental factors [J]. Int J Androl, 2006, 29(1):278-285, 286-290.
|
|
33 Cupisti S, Haberle L, Dittrich R, et al. Smoking is associated with increased free testosterone and fasting insulin levels in women with polycystic ovary syndrome, resulting in aggravated insulin resistance[J]. Fertil Steril, 2010, 94(2):673-677.
|
|
34 Glintborg D, Andersen M. An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome[J]. Gynecol Endocrinol, 2010, 26(4):281-296.
|
|
35 Zhuang J, Xu LZ, Kang DY, et al. Systematic review of desogestrel ethinylestradiol for treating polycystic ovary syndrome [J/CD]. Chin J Obstet Gynecol Pediatr (Electron Ed), 2009, 5(1): 55-63. [庄静，许良智，康德英，等.去氧孕烯炔雌醇治疗多囊卵巢综合征的系统评价[J/CD].中华妇幼临床医学杂志：电子版，2009，5(1)：55-63.]
|
|
36 Simoni M, Tempfer CB, Destenaves B, et al. Functional genetic polymorphisms and female reproductive disorders: Part I:Polycystic ovary syndrome and ovarian response[J]. Hum Reprod Update, 2008,14(5) :459-484.
|
|
37 Goodarzi MO. Looking for polycystic ovary syndrome genes:Rational and best strategy[J]. Semin Reprod Med, 2008, 26(1) :5-13.
|
|
38 Deligeoroglou E, Kouskouti C,Christopoulos P. The role of genes in the polycystic ovary syndrome: Predisposition and mechanisms [J]. Gynecol Endocrinol,2009,25(9) :603-609.
|
|
39 Xu LZ, Liu Y, Zhang J. Evidence-based medicine evaluation of treatment strategy of polycystic ovarian syndrome[J]. Pract J Clin Med,2008,5(6):22-25. [许良智，刘颖，张静.多囊卵巢综合征治疗循证医学评价[J].实用医院临床杂志，2008，5(6) :22-25.]
|
|
40 Palomba S, Falbo A, Giallauria F, et al. Six weeks of structured exercise training and hypocaloric diet increases the probability of ovulation after clomiphene citrate in overweight and obese patients with polycystic ovary syndrome: A randomized controlled trial[J]. Hum Reprod,2010,25(11) :2783-2791.
|
|
41 Palomba S, Giallauria F, Falbo A, et al. Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: A 24-week pilot study[J]. Hum Reprod,2008,23(3) :642-650.
|
|
42 Lord JM, Norman R. Obesity, polycystic ovary syndrome, infertility treatment: Lifestyle modification is paramount [J]. BMJ,2006,332(7541) :609.
|
|
43 Karimzadeh MA, Javedani M. An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome[J]. Fertil Steril, 2010, 94(1) :216-220.
|
|
44 Moran LJ, Hutchison SK, Norman RJ, et al. Lifestyle changes in women with polycystic ovary syndrome [J]. Cochrane Database Syst Rev,2011,2:7506.
|
|
45 Thomson RL, Buckley JD, Brinkworth GD. Exercise for the treatment and management of overweight women with polycystic ovary syndrome: A review of the literature[J]. Obest Rev, 2011, 12(5):202-210.
|
|
46 Harrison CL, Lombard CB, Moran LJ, et al. Exercise therapy in polycystic ovary syndrome: A systematic review[J]. Hum Reprod Update, 2011,17(2) :171-183.
|
|
47 Jasik CB, Lustig RH. Adolescent obesity and puberty: The "perfect storm"[J]. Ann Ny Acad Sci,2008,1135:265-279.
|
|
48 Diamanti-Kandarakis E, Economou F, Palimeri S, et al. Metform8in in polycystic ovary syndrome[J]. Ann Ny Acad Sci, 2010,1205:192-198.
|
|
49 Ojaniemi M, Tapanainen P, Morin-Papunen L. Management of polycystic ovary syndrome in childhood and adolescence[J]. Horm Res Paediatr,2010, 74(5):372-375.
|
|
50 Nestler JE. Metformin for the treatment of the polycystic ovary syndrome[J]. New Engl J Med,2008,358(1):47-54.
|
|
51 Diamanti-Kandarakis E, Christakou CD, Kandaraki E, et al. Metformin: An old medication of new fashion: Evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome[J]. Eur J Endocrinol,2010,162(2): 193-212.
|
|
52 Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility[J]. Cochrane Database Syst Rev,2010(1):3053.
|
|
53 Elizur SE, Tulandi T. Drugs in infertility and fetal safety [J]. Fertil Steril,2008,89(6): 1595-1602.
|
|
54 Cheung NW. The management of gestational diabetes [J]. Vasc Health Risk Manag,2009,5(1): 153-164.
|
|
55 Sahin I,Serter R,Karakurt F, et al. Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: A randomized prospective study[J]. Gynecol Endocrinol,2004, 19(3) : 115-124.
|
|
56 Ibanez L, Valls C, Ferrer A, et al. Additive effects of insulinsensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation[J]. J Clin Endocrinol Metab,2002,87(6) :2870-2874.
|
|
57 Ibanez L, Potau N, Marcos MV, et al. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: Effect of flutamide [J]. J Clin Endocrinol Metab,2000,85(9):3251-3255.
|
|
58 Nader S. Ovulation induction in polycystic ovary syndrome [J]. Minerva Ginecol,2008,60(1) :53-61.
|
|
59 Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome [J]. New Engl J Med,2007,356(6) :551-566.
|
|
60 Radosh L. Drug treatments for polycystic ovary syndrome[J]. Am Fam Physician, 2009,79(8) :671-676.
|
|
61 Moran LJ, Noakes M, Clifton PM, et al. The effect of modifying dietary protein and carbohydrate in weight loss on arterial compliance and postprandial lipidemia in overweight women with polycystic ovary syndrome [J]. Fertil Steril, 2010, 94 ( 6): 2451-2454.
|
|
62 Wild RA,Carmina E,Diamanti-Kandarakis E,et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the androgen excess and polycystic ovary syndrome ( AE-PCOS) society [J]. J Clin Endocrinol Metab,2010,95(5) :2038-2049.
|
|
63 Sharma ST,Nestler JE. Prevention of diabetes and cardiovascular disease in women with PCOS: Treatment with insulin sensitizers [J]. Best Pract Res Cl En,2006,20(2):245-260.
|